Partners Keith Zullow and Michael Cottler discuss how disputes often arise regarding what is required of a biosimilar applicant to comply with subsection (l)(2)(A) of the BPCIA, a provision that kicks off the patent dance. Although this issue arises frequently in litigation, it is unclear whether courts will ever resolve it.
Read the full article here.